TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2827045

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 58

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 58
Study: 29429389

Group type: EXPERIMENTAL
Intervention: Scientist-practitioner program
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Practitioner program
Number of subjects: 453

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 453
Study: 30216294

Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 1684

Group type: COMPARATOR
Intervention: HIV-exposed, uninfected infants
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: HIV-infected infants with in utero infection
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: HIV-infected infants with intrapartum infection
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: HIV in utero-infected infants
Number of subjects: 1684
Study: 26808865

Group type: EXPERIMENTAL
Intervention: Raw milk with drug residues (DR) containing ceftiofur, penicillin, ampicillin, and oxytetracycline at concentrations of 0.1, 0.005, 0.01, and 0.3 μg/ml respectively
Number of subjects: 30

Group type: COMPARATOR
Intervention: Raw milk with no drug residues (NR)
Number of subjects: 30
Study: 25562388

Group type: EXPERIMENTAL
Intervention: Individualized home-based balance and strengthening exercise program with intermittent home-visit support by a physiotherapist
Number of subjects: 71

Group type: COMPARATOR
Intervention: Previous RCT results
Number of subjects: 71
Study: 24089302

Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronan injection (HS)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Therapeutic wrist arthroscopy without additional treatment (A-group)
Number of subjects: 140
Study: 20522296

Group type: EXPERIMENTAL
Intervention: Locally produced soy/peanut ready-to-use supplementary food (RUSF) at a dosage of 65 kcal/kg/d for up to 8 weeks.
Number of subjects: 2417
Study: 18622133

Group type: EXPERIMENTAL
Intervention: Singing bowl therapy (IG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo treatment (KG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (NG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Singing bowl therapy (IG) and Placebo treatment (KG)
Number of subjects: 54
Study: 16174119

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) measurement
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: E/Ea ratios (lateral, septal, average)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Average E/Ea ratio
Number of subjects: 70
Study: 14652498

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing mixed tocopherols, flavonoids, and docosahexaenoate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10962306

Group type: EXPERIMENTAL
Intervention: MLP model
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: LR model
Number of subjects: 656

Group type: COMPARATOR
Intervention: Proportion of free PSA
Number of subjects: 656
Study: 8844499

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Methylprednisolone combined with cyclophosphamide
Number of subjects: 28
Study: 1510514

Group type: EXPERIMENTAL
Intervention: Intravenous administration of rHuEPO (100 U.kg‐1.day‐1) and intravenous iron preparations for 14 days before operation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rHuEPO (600 U/kg) on preoperative days 14 and 7 and oral iron preparations for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral iron preparations alone
Number of subjects: 40
Study: 6837235

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural analgesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 31153127

Group type: EXPERIMENTAL
Intervention: Unusual actions performed by a model using her head or sitting on the apparatus (hands-occupied condition)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Unusual actions performed by a model using her hands (hands-free condition)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Gaze behavior directed at the model after reenacting the observed action
Number of subjects: 293
Study: 29946818

Group type: EXPERIMENTAL
Intervention: Continuous administration (CA) of intravenous iron: 100 mg sucrose iron agents during every HD session, total dose of 1000 mg.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intermittent administration (IA) of intravenous iron: 100 mg sucrose iron agents once every week, total dose of 1000 mg.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both CA and IA
Number of subjects: 41
Study: 27090417

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) training for 6 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 35
Study: 24664093

Group type: EXPERIMENTAL
Intervention: Doctor Office Collaborative Care (DOCC)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 321
Study: 22972443

Group type: EXPERIMENTAL
Intervention: Telephone intervention (7 dietary counseling calls)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Face-to-face intervention (7 one-to-one dietary counseling sessions)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care (no additional contact)
Number of subjects: 87
Study: 21199119

Group type: EXPERIMENTAL
Intervention: 1.5% sevoflurane
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1.25% sevoflurane
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1.0% sevoflurane
Number of subjects: 96
Study: 17657963

Group type: EXPERIMENTAL
Intervention: Glutoxim, 60 mg/day for 52 days
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 118
Study: 15768874

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized control trial
Number of subjects: 0
Study: 12357714

Group type: EXPERIMENTAL
Intervention: ipratropium bromide (IB) 0.6% nasal spray
Number of subjects: 22

Group type: COMPARATOR
Intervention: vehicle (placebo)
Number of subjects: 22
Study: 10828701

Group type: EXPERIMENTAL
Intervention: Multiplex polymerase chain reaction assay
Number of subjects: 100
Study: 9190003

Group type: EXPERIMENTAL
Intervention: Oral dose of 40 mg of prednisone
Number of subjects: 17
Study: 8476830

Group type: EXPERIMENTAL
Intervention: Endometrial resection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 200
Study: 3081622

Group type: EXPERIMENTAL
Intervention: Continuous hyperventilation to maintain PaCO2 between 3.5 and 5 kPa
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mechanical ventilation only if severe hypoxia or hypercapnia occurred (Control)
Number of subjects: 20
Study: 29277553

Group type: EXPERIMENTAL
Intervention: Euhydration (EUH) - drinking 2500ml/24h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON) - monitoring food and fluid intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dehydration (DEH) - minimizing drinking
Number of subjects: 12
Study: 27487479

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 24470281

Group type: EXPERIMENTAL
Intervention: EPA-FFA 2 g daily
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 24354714

Group type: EXPERIMENTAL
Intervention: Intralesional cryotherapy
Number of subjects: 176

Group type: COMPARATOR
Intervention: Excision and corticosteroids
Number of subjects: 176

Group type: COMPARATOR
Intervention: Excision and brachytherapy
Number of subjects: 176
Study: 20226475

Group type: EXPERIMENTAL
Intervention: Ventral cardiac denervation in addition to coronary artery bypass grafting
Number of subjects: 220

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting only (Control)
Number of subjects: 220
Study: 18688562

Group type: EXPERIMENTAL
Intervention: Gastrografin (GG)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional treatment (TT)
Number of subjects: 76
Study: 16651509

Group type: EXPERIMENTAL
Intervention: Sertraline (n = 79)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (n = 73)
Number of subjects: 152
Study: 14717039

Group type: EXPERIMENTAL
Intervention: Brief information and occlusal appliance
Number of subjects: 864

Group type: COMPARATOR
Intervention: Brief information only
Number of subjects: 864

Group type: COMPARATOR
Intervention: Brief information and relaxation therapy
Number of subjects: 864
Study: 10815366

Group type: EXPERIMENTAL
Intervention: Computer-based clinical decision support system (CDSS)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1034
Study: 8784075

Group type: EXPERIMENTAL
Intervention: Single injection of recombinant human GH (0.03 mg/kg, sc)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3 months of recombinant human GH (0.03 mg/kg, sc, 3 x /week)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1624721

Group type: EXPERIMENTAL
Intervention: Ritodrine plus magnesium gluconate
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ritodrine alone
Number of subjects: 107
Study: 31705219

Group type: EXPERIMENTAL
Intervention: Steroid switch from prednisone to dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 0
Study: 29627721

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (strategies against stigma and discrimination, psycho-education, social skills training, cognitive behavioral therapy)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Face to face interview (control group)
Number of subjects: 327
Study: 26866731

Group type: EXPERIMENTAL
Intervention: Teaching intervention for handoff communication skills
Number of subjects: 0
Study: 25010430

Group type: EXPERIMENTAL
Intervention: Integrated cognitive-behavioral therapy (CBT) and voucher-based reinforcement therapy (VBRT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) with attendance-based reward program
Number of subjects: 59
Study: 22158090

Group type: EXPERIMENTAL
Intervention: Trekking boots (TBs) on level natural terrain at several speeds (0.28, 0.56, 0.84, 1.11, and 1.39 m·s(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Treadmill at various raising slopes (0, 1, 2, 3, 4%) while wearing running shoes
Number of subjects: 14
Study: 20863381

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day (n = 42)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Increase in dose of other oral agents (n = 39)
Number of subjects: 88
Study: 18547272

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 317
Study: 16169327

Group type: EXPERIMENTAL
Intervention: Nicorandil (15 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Isosorbide mononitrate (40 mg/d)
Number of subjects: 36
Study: 14750461

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10329041

Group type: EXPERIMENTAL
Intervention: Elevated CA125 group
Number of subjects: 771

Group type: COMPARATOR
Intervention: Control group (normal CA125 levels)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Elevated CA125 group (excluding preexisting morbid conditions)
Number of subjects: 771
Study: 8904586

Group type: EXPERIMENTAL
Intervention: Eccentric training (n = 14)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Concentric training (n = 14)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-exercising control group (n = 14)
Number of subjects: 42
Study: 1906905

Group type: EXPERIMENTAL
Intervention: 0.4 or 0.8 mg of nitroglycerin
Number of subjects: 23

Group type: COMPARATOR
Intervention: 2 mg/kg of cocaine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intranasal saline solution
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sublingual placebo
Number of subjects: 23
Study: 6652641

Group type: EXPERIMENTAL
Intervention: Symptom duration prior to treatment in patients with slower-growing tumors
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Symptom duration prior to treatment in patients with faster-growing tumors
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Breast cancer control activities to decrease the interval from recognition of symptoms to diagnosis and treatment
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Early diagnosis and treatment during the symptomatic period for patients with faster-growing tumors
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Detection of asymptomatic cancer for patients with faster-growing tumors
Number of subjects: 160
Study: 31278224

Group type: EXPERIMENTAL
Intervention: 1 mg vitamin K (n=41)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No vitamin K (n=39)
Number of subjects: 80
Study: 29574355

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg/d) plus trifluoperazine (5 mg/d)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/d) alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Weight change at week 2
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Weight gain at week 6
Number of subjects: 94
Study: 26908914

Group type: EXPERIMENTAL
Intervention: GLP-1 (0.8 pmol/kg/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 24634003

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day, 4 weeks on/2 weeks off)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Interferon α (9 MU subcutaneously 3 times per week)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 735
Study: 22360330

Group type: EXPERIMENTAL
Intervention: Combined actives (Furcellaria lumbricalis, Fucus vesiculosus, retinoid, conjugated linoleic acid, glaucine mixture)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fucus vesiculosus and Furcellaria lumbricalis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glaucine mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined actives
Number of subjects: 0
Study: 20585005

Group type: EXPERIMENTAL
Intervention: Glutamine (0.25 g/kg/dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16482098

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 22

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 22
Study: 12950959

Group type: EXPERIMENTAL
Intervention: Extracorporeal albumin dialysis (ECAD)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (untreated patients with ESLD)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 11
Study: 10712326

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual medical care (UMC)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) for hypoxemic ARF
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual medical care (UMC) for hypoxemic ARF
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) for hypercapnic ARF
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual medical care (UMC) for hypercapnic ARF
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) for non-COPD ARF
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual medical care (UMC) for non-COPD ARF
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) for COPD
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual medical care (UMC) for COPD
Number of subjects: 61
Study: 8998115

Group type: EXPERIMENTAL
Intervention: Adjuvant interferon-alpha-2b (IFN-alpha-2b)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elective lymph node dissection (ELND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 0
Study: 1547301

Group type: EXPERIMENTAL
Intervention: Lithium discontinuation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3903785

Group type: EXPERIMENTAL
Intervention: Triletide (1.5 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbenoxolone (0.3 g/day)
Number of subjects: 20
Study: 31640312

Group type: EXPERIMENTAL
Intervention: Cyclic stretching (CS) program, 2 min of CS of the plantar flexor muscles, 5 times a week for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 30819356

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA)
Number of subjects: 1908

Group type: COMPARATOR
Intervention: Functional stress testing
Number of subjects: 1908
Study: 27856714

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 15 l/min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 30 l/min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 45 l/min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF)
Number of subjects: 13
Study: 25733675

Group type: EXPERIMENTAL
Intervention: Causal analysis
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Intent-to-treat analysis
Number of subjects: 10000
Study: 23460810

Group type: EXPERIMENTAL
Intervention: Xiaoke Pill
Number of subjects: 800

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 800
Study: 23113085

Group type: EXPERIMENTAL
Intervention: Closure of the Broken Hill Proprietary (BHP) steel industry
Number of subjects: 0
Study: 18950663

Group type: EXPERIMENTAL
Intervention: Explicit learning of a sequence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Procedural sequence learning
Number of subjects: 0
Study: 17076840

Group type: EXPERIMENTAL
Intervention: InDel-based assay panel
Number of subjects: 73
Study: 15214204

Group type: EXPERIMENTAL
Intervention: Renovated environment with a new dementia care unit and decentralized dining areas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renovated environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decentralized neighborhood design
Number of subjects: 0
Study: 11990832

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) therapy
Number of subjects: 0
Study: 9647030

Group type: EXPERIMENTAL
Intervention: Colestid Granules
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8122598

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 39
Study: 2527531

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg oral dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazaprilat (equivalent oral and intravenous doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazaprilat (oral)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril (oral)
Number of subjects: 12
Study: 1071709

Group type: EXPERIMENTAL
Intervention: Severe hypertension and renal impairment in pregnancy (pre-eclampsia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncomplicated essential hypertension in pregnancy
Number of subjects: 0
Study: 30672254

Group type: EXPERIMENTAL
Intervention: Fan-needle radiofrequency guided by meridians-muscles theory, treated at tendon nodes around knee joints (ashi points), 4 points per treatment, once every two weeks for 2 treatments.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral administration of celecoxib capsules, 1 capsule every day for 4 weeks.
Number of subjects: 100
Study: 29131826

Group type: EXPERIMENTAL
Intervention: Interactive sports video game (IVG; Nintendo Wii™ Sports Resort)
Number of subjects: 8
Study: 25457473

Group type: EXPERIMENTAL
Intervention: vildagliptin/metformin (50/1000 mg twice daily) SPC
Number of subjects: 99

Group type: COMPARATOR
Intervention: sitagliptin/metformin (50/1000 mg twice daily) SPC
Number of subjects: 99
Study: 24284855

Group type: EXPERIMENTAL
Intervention: Acute pain exposure (VAS or VRS score > 0)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 151

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 151
Study: 21884601

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 4209
Study: 18658043

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/d
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 17035949

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day for 1 year)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Angiotensin‐converting enzyme inhibitors and/or angiotensin type 1 receptor antagonists alone
Number of subjects: 83
Study: 14604448

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 169
Study: 11258635

Group type: EXPERIMENTAL
Intervention: Rescue Lifting System (RLS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional techniques (Lifesling and navy rescue system)
Number of subjects: 14
Study: 9205627

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 24
Study: 7966668

Group type: EXPERIMENTAL
Intervention: Isothermic transurethral prostatectomy (warmed irrigant at 38C)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard transurethral prostatectomy (ambient temperature irrigant at 21C)
Number of subjects: 52
Study: 3334952

Group type: EXPERIMENTAL
Intervention: Informational intervention with four messages during radiation therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine information provided to control patients
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Informational intervention
Number of subjects: 84
Study: 30957167

Group type: EXPERIMENTAL
Intervention: Delafloxacin 300 mg IV every 12 hours (Study 302); 300 mg IV every 12 hours for 3 days, then 450 mg orally every 12 hours (Study 303)
Number of subjects: 1510

Group type: EXPERIMENTAL
Intervention: Delafloxacin
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Vancomycin/aztreonam
Number of subjects: 1510
Study: 29173037

Group type: EXPERIMENTAL
Intervention: Mixed-sex intervention (including women)
Number of subjects: 262

Group type: COMPARATOR
Intervention: All-male intervention
Number of subjects: 262